Your browser doesn't support javascript.
loading
Distinct immune cell dynamics correlate with the immunogenicity and reactogenicity of SARS-CoV-2 mRNA vaccine.
Takano, Tomohiro; Morikawa, Miwa; Adachi, Yu; Kabasawa, Kiyomi; Sax, Nicolas; Moriyama, Saya; Sun, Lin; Isogawa, Masanori; Nishiyama, Ayae; Onodera, Taishi; Terahara, Kazutaka; Tonouchi, Keisuke; Nishimura, Masashi; Tomii, Kentaro; Yamashita, Kazuo; Matsumura, Takayuki; Shinkai, Masaharu; Takahashi, Yoshimasa.
Affiliation
  • Takano T; Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Morikawa M; Tokyo Shinagawa Hospital, Tokyo 140-8522, Japan.
  • Adachi Y; Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Kabasawa K; Tokyo Shinagawa Hospital, Tokyo 140-8522, Japan.
  • Sax N; KOTAI Biotechnologies, Inc., Osaka 565-0871, Japan.
  • Moriyama S; Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Sun L; Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Isogawa M; Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Nishiyama A; Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Onodera T; Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Terahara K; Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Tonouchi K; Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Nishimura M; Tokyo Shinagawa Hospital, Tokyo 140-8522, Japan.
  • Tomii K; Artificial Intelligence Research Center (AIRC), National Institute of Advanced Industrial Science and Technology (AIST), Tokyo 135-0064, Japan; AIST-Tokyo Tech Real World Big-Data Computation Open Innovation Laboratory (RWBC-OIL), Tokyo 152-8550, Japan.
  • Yamashita K; KOTAI Biotechnologies, Inc., Osaka 565-0871, Japan.
  • Matsumura T; Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo 162-8640, Japan. Electronic address: matt@niid.go.jp.
  • Shinkai M; Tokyo Shinagawa Hospital, Tokyo 140-8522, Japan. Electronic address: shinkai050169@gmail.com.
  • Takahashi Y; Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo 162-8640, Japan. Electronic address: ytakahas@niid.go.jp.
Cell Rep Med ; 3(5): 100631, 2022 05 17.
Article in En | MEDLINE | ID: mdl-35545084
Two doses of Pfizer/BioNTech BNT162b2 mRNA vaccine elicit robust severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-neutralizing antibodies with frequent adverse events. Here, by applying a high-dimensional immune profiling on 92 vaccinees, we identify six vaccine-induced immune dynamics that correlate with the amounts of neutralizing antibodies, the severity of adverse events, or both. The early dynamics of natural killer (NK)/monocyte subsets (CD16+ NK cells, CD56high NK cells, and non-classical monocytes), dendritic cell (DC) subsets (DC3s and CD11c- Axl+ Siglec-6+ [AS]-DCs), and NKT-like cells are revealed as the distinct cell correlates for neutralizing-antibody titers, severity of adverse events, and both, respectively. The cell correlates for neutralizing antibodies or adverse events are consistently associated with elevation of interferon gamma (IFN-γ)-inducible chemokines, but the chemokine receptors CCR2 and CXCR3 are expressed in distinct manners between the two correlates: vaccine-induced expression on the neutralizing-antibody correlate and constitutive expression on the adverse-event correlate. The finding may guide vaccine strategies that balance immunogenicity and reactogenicity.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: COVID-19 / BNT162 Vaccine Type of study: Prognostic_studies Limits: Humans Language: En Journal: Cell Rep Med Year: 2022 Document type: Article Affiliation country: Japan Country of publication: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: COVID-19 / BNT162 Vaccine Type of study: Prognostic_studies Limits: Humans Language: En Journal: Cell Rep Med Year: 2022 Document type: Article Affiliation country: Japan Country of publication: United States